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Background: The reliable assessment of iron deﬁciency (ID) and the iron parameters which contribute to
anaemia in preterm and term infants are of vital importance.
Aim of the study: This study focuses on identifying maternal and cord blood hepcidin [Hep (CB)] levels
based on gestational weeks (GW) and comparing them with other parameters in iron metabolism.
Patients & methods: This is a prospective and observational study including 102 pregnant women and
their infants. Along with Hep(CB), iron, iron chelation capacity, ferritin, transferrin saturation, C-reactive
protein level were recorded for mothers and infants.
Results: Maternal and cord blood hepcidin levels were 135.0 ng/ml (6.40e2846.0) and 286.30 ng/ml (90
e1697) for those under 33 GW (n ¼ 27), 66.4 ng/ml (11.0e3936.0) and 406.9 ng/ml (10.0e1867) for those
between 33 and 37 GW (n ¼ 33), 41.4 ng/ml (2.8e513.7) and 498.1 ng/ml (343.7e701.7) for those over
37 GW (n ¼ 42), respectively. Hep(CB) [104.7 ng/ml (5.0e1022.0), n ¼ 22] levels were lower for infants
with ID compared to those without iron deﬁciency [463.3 ng/ml (131.3e2261.0), p < 0.0001, n ¼ 80)].
While a strongly positive relationship was observed between Hep(CB) levels and cord blood ferritin
levels (Rho ¼ 0.76, p < 0.0001) in the correlation analysis, a weak relationship (Rho ¼ 0.29, p ¼ 0.004)
was found for transferrin saturation. Additionally, it was observed that Hep(CB) levels were directly
proportional to GW (Rho ¼ 0.23, p < 0.0001) and birth weight (Rho ¼ 0.21, p ¼ 0.03). A decrease of 10
units in Hep(CB) level increases risk for ID anaemia by 5% [OR ¼ 0.95 (0.9297e0.98099)].
Conclusions: This study, which compares Hep(CB) levels and iron parameters based on GWs, differs from
similar studies in terms of assessment of both preterm and term groups along with maternal levels. It is
evident that increase in hepcidin prevents ID anaemia.
© 2016 Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).s), drozdemir564@gmail.com
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Hepcidin is a regulator of iron metabolism. It inhibits iron
transport by binding to the iron export channel ferroportin located
on the basolateral surface of gut enterocytes and the plasma
membrane of macrophages. Hepcidin ultimately breaks down the
transporter protein in the lysosome. Inhibiting ferroportin prevents
iron from being exported, and the iron is sequestered in the cells
[1,2]. It was reported that rat hepcidin level was the negative
regulator of iron absorption in the intestines, iron transfer across
placenta and iron emission from macrophages [3].
Hepcidin affects plasma iron concentration and tissue distri-
bution of iron by inhibiting intestinal iron absorption, iron recyclingics. Production and hosting by Elsevier B.V. This is an open access article under the
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Increase in hepcidin levels during inﬂammation stimulates ferro-
portin intake and degradation in the cell in macrophages, hepato-
cyte and duodenal enterocytes, and leads to iron retention in these
cells and decreases iron transmission to the plasma [5]. There is a
total iron of 1 g in an infant's body during the birth, which is
transmitted from the mother to the infant through the placenta [6].
It is created by a maternal diet of 600 mg and cessation of
menstruation, and 400 mg is provided by maternal stores [6].
Several studies demonstrate that iron supplementation prevents
prematurity and birth complication [7e9]. Decreases in iron levels
lead to mental retardation and mental problems during adoles-
cence [10,11].
Considerably high iron level, i.e. applying iron supplementation
to a non-anaemic mother, may lead to negative results such as low
birth weight and gestational diabetics [12]. Fetal iron levels are
regulated by hepcidin synthesis in the liver, and hepcidin is pro-
duced as iron levels decrease. Hepcidin interacts with placenta
through an unknown mechanism when it is transmitted to the
circulatory system [13]. Therefore, hepcidin hormone, which in-
ﬂuences iron metabolism, is of vital importance for mothers and
newborns.
This study focuses on identifying levels of hepcidin hormone,
which fulﬁls both iron and host defence and an anti-microbial
function in the body, in mothers and newborns based on gesta-
tional weeks, and the relationship between iron metabolism and a
mother-newborn.
2. Materials and methods
This study was approved by the decision of Erciyes University
Faculty of Medicine Ethical Committee taken on 21.12.2010 and
numbered 2010/22, and was supported by Erciyes University Fac-
ulty of Medicine Committee of Scientiﬁc Research Projects with the
project number TSU-11-3485.
2.1. Study population
One hundred and two pregnant women, who were monitored
between May 2011 and July 2011 at Gevher Nesibe Hospital Peri-
natology Department and whose GWs range from 27 þ 0/7 to
41 þ0/7, and their infants were included in the study. The mothers'
demographic features were identiﬁed based on the anamnesis and
the existence of any early membrane rupture (EMR) and cho-
rioamnionitis. Infants who were diagnosed with congenital
anomaly in foetal ultrasonography (USG) or during birth and
pregnant women with EMR or chorioamnionitis were not included
in the study. Gestational complications were categorised as dia-
betes, hypertension, pre-eclampsia, liver dysfunction and other
complications. Women who developed pregnancy complications
were excluded from the study.
2.2. Maternal and cord blood measurements
Total blood volumes of 7 ml and 5 ml were taken from the
mothers and cords, respectively. In addition to hepcidin values, the
Human Hepcidin ELISA kit was used to measure hepcidin level in
the samples taken from themother 24-h prior to the birth and from
the cord during the birth for complete blood count, iron, iron
chelation capacity, transferrin saturation, ferritin and CRP as an
infection marker. Hepcidin serum samples were stored at 80 C
for 3 months. The stored samples were later utilised for the mea-
surement of hepcidin levels. Tests were performed with Hepcidin
Prohormone ELISA (Solid Phase Enzyme-Linked Immunosorbent
Assay) kits manufactured by USCN Life Science (USCN life Science,Inc., Wuhan, China) with the code number E 91979 Hu. Measurable
ranges of hepcidinwere 0e1000 ng/mL. The analytical sensitivity of
hepcidin was found as <3.95 ng/mL, as given by the manufacturer.
2.3. Statistical analysis
Normal distribution suitability of the data was measured with
the ShapiroeWilk test. Data were expressed as mean ± standard
deviation, median (25th percentilee75th percentile), frequency
and percentages. ManneWhitney U One-way variance analysis and
the KruskaleWallis H test were used for the comparison of
abnormally distributed data variables. The Spearman rank test was
used for correlation analysis. p < 0.05 was considered as mean-
ingful in the data analysis.
3. Results
A total of 102 infants and mothers were included in the study.
Pregnant women were divided into three groups: 27 pregnant
women under 33 weeks, 33 pregnant women between 33 and 37
weeks and 42 pregnant women over 37 weeks. The demographic
features of the study population based on GW are given in Table 1,
and the comparison of haematologic and biochemical parameters
are given in Table 2 and Table 3, respectively.
Maternal and cord blood hepcidin levels were 135.0 ng/ml
(6.40e2846.0) and 286.30 ng/ml (90e1697) for those under 33 GW
(n¼ 27), 66.4 ng/ml (11.0e3936.0) and 406.9 ng/ml (10.0e1867) for
those between 33 and 37 GW (n ¼ 33), 41.4 ng/ml (2.8e513.7) and
498.1 ng/ml (343.7e701.7) for those over 37 GW (n ¼ 42),
respectively.
Hep(CB) [104.7 ng/ml (5.0e1022.0), n ¼ 22] levels were lower
for infants with ID (cord ferritin<60 mg/l) compared to those
without iron deﬁciency (cord ferritin60 mg/l) [463.3 ng/ml
(131.3e2261.0), p < 0.0001, n ¼ 80)]. While a strongly positive
relationship was observed between Hep(CB) levels and cord blood
ferritin levels (Rho ¼ 0.76, p < 0.0001) in the correlation analysis, a
weak relationship (Rho¼ 0.29, p¼ 0.004) was found for transferrin
saturation. Additionally, it was observed that Hep(CB) levels were
directly proportional to GW (Rho ¼ 0.23, p < 0.0001) and birth
weight (Rho ¼ 0.21, p ¼ 0.03). Speciﬁc reference values based on
GW are given in Table 4. A decrease of 10 units in Hep(CB) level
increases risk for ID anaemia by 5% [OR ¼ 0.95 (0.9297e0.98099)].
Furthermore, no correlation was observed among Hep(CB)
levels and delivery method, mean corpuscular volume (MCV), cord
blood iron and iron binding capacity. No statistically signiﬁcant
difference was observed in the hepcidin levels of infants delivered
by mothers with ID [Maternal ferritin<30 mg/l]. In addition, no
relationship was observed between mothers' iron and Hep(CB)
levels.
Hep(M) and maternal ferritin levels decrease as GW increases,
and these parameters are inversely proportional to Hep(CB). When
hepcidin levels in maternal and cord blood were compared, it was
found that the maternal hepcidin level was lower than the cord
hepcidin level. No relationship was found between maternal and
cord hepcidin levels.
4. Discussion
This study demonstrated that the increased levels of hepcidin
prevented iron deﬁciency. There are many diseases in which
inadequate iron absorption contributes to iron deﬁciency and
anaemia. The treatment depends on the present hepcidin levels as
oral treatment is unlikely to be effective when hepcidin blocks the
enteral absorption. Parenteral iron treatment would be more
appropriate for this treatment [2]. Our study found out that
Table 1
Demographic features according to gestational age.
<33 GW (n ¼ 27) mean ± SD 33e37 GW (n ¼ 33) mean ± SD >37 GW (n ¼ 42) mean ± SD p
Mode of delivery <0.0001
NSVD 3 6 4
ElCS 2a 12b 36c
EmCS 22a 15b 2c
Sex 0.90
Male (n ¼ 59) 11 15 17
Female (n ¼ 43) 16 18 25
Birth weight (gr) 1400 ± 478a 2185 ± 504b 3273 ± 559c <0.0001*
Maternal age (year) 25.6 ± 5.8a 28.1 ± 5.8a,b 29.6 ± 6.0b 0.025*
GW: Gestational weeks, NSVD: Normal spontaneous vaginal delivery, ElCS: Elective Caesarean section, EmCS: Emergency Caesarean section.
Chi-Square test. p value obtained by Fisher's Exact test.
*p value obtained by One-Way Anova test.
The bold values and letters ‘a, b, c’ shows that signiﬁcant differences between the three groups.
Table 2
Comparison of haematological parameters.
<33 GW (n ¼ 27) 33e37 GW (n ¼ 33) >37 GW (n ¼ 42) p
Hb(M) (mg/dl) 11.4 ± 1.3 12.0 ± 1.7 11.4 ± 1.6 0.22
Hb(CB) (mg/dl) 15.3 ± 1.6 15.2 ± 2.5 15.2 ± 1.8 0.98
Fe(M) (mcgr/dl) 53.0 (34.5e108.0) 68.0 (36.5e121.0) 61.0 (37.2e95.0) 0.77*
Fe(CB) (mcgr/dl) 120.7 ± 74.5 141.8 ± 52.5 147.0 ± 33.6 0.12
FeBC(M) (ug/dl) 420.0 ± 83.0 428.1 ± 77.2 425.8 ± 103.1 0.94
FeBC(CB) (ug/dl) 187.0 ± 96.3 212.0 ± 65.6 210.4 ± 68.8 0.37
MCV(M) (ﬂ) 92.0 (88.8e93.7)a 88 (84.8e92.3)a,b 87.0 (82.9e91.7)b 0.01*
MCV(CB) (ﬂ) 115.2 ± 10.3a 113.0 ± 7.64a,b 110.3 ± 5.3b 0.03
GW: Gestational weeks, Hb(M): Maternal haemoglobin, Hb(CB): Cord blood haemoglobin Fe(M): Maternal iron, Fe(CB): Cord blood iron FeBC(M): Maternal iron binding
capacity, FeBC(CB): Cord blood iron binding capacity MCV(M): Maternal mean corpuscular volume, MCV(CB): Cord blood mean corpuscular volume.
Normally distributed data were expressed as mean ± standard deviation. Non-normally distributed data were expressed as mean ± standard deviation.
p value obtained by One-Way Anova test.
*p value obtained by KruskaleWallis test.
The bold values and letters ‘a, b, c’ shows that signiﬁcant differences between the three groups.
Table 3
Comparison of biochemical parameters.
<33 GW (n ¼ 27) Median (25e75p) 33e37 GW (n ¼ 33) Median (25e75p) >37 GW (n ¼ 42) Median (25e75p) p
Hep(M) (ng/ml) 135.0 (88.4e188.25)a,b 66.4 (45.7e385.8)a 41.4 (18.4e100.0)b <0.0001
Hep(CB) (ng/ml) 286.3 (211.4e457.4) 406.9 (198.2e686.8) 498.1 (343.7e701.7) 0.053
Ferritin(M) (mcgr/ml) 34.4 (23.1e42.2)c 28.5 (13.4e83.4)a 14.5 (9.4e28.4)b 0.002
Ferritin(CB) (mcgr/ml) 98.0 (77.8e136.1) 108.4 (34.9e176.7) 132.6 (84.1e192.0) 0.35
Transferrin Sat(M) % 0.12 (0.08e0.2) 0.18 (0.09e0.29) 0.14 (0.08e0.22) 0.60
Transferrin Sat(CB) % 0.82 (0.4e0.8) 0.71 (056e0.90) 0.77 (0.56e0.95) 0.64
GW: Gestational weeks, Hep(M): Maternal hepcidin, Hep(CB): Cord blood hepcidin, Ferritin(M): Maternal ferritin, Ferritin(CB): Cord blood ferritin, Transferrin Sat(M):
Maternal transferrin saturation, Transferrin Sat(CB): Cord blood transferrin saturation.
The bold values and letters ‘a, b, c’ shows that signiﬁcant differences between the three groups.
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provided data on speciﬁc reference ranges of gestational weeks
for hepcidin level in term and preterm infants. This study differs
from similar studies in terms of its assessment on both preterm
and term groups along with maternal levels. Therefore, it is the
ﬁrst study on this topic in the literature. Increase in erythropoietic
activity reduces hepcidin levels signiﬁcantly. A single adminis-
tration of erythropoietin on a daily period reduces hepcidin levelsTable 4
GW-speciﬁc reference ranges for hepcidin by percentile.
GW (weeks) n Hep(CB) ng/ml
5p 10p 25p 50p 75p 90p 95p
<33 27 104.4 141.7 211.4 308.1 457.4 755.2 1513.1
33e37 33 28.6 43.4 198.2 406.9 686.8 1422.0 1774.1
>37 42 32.9 78.2 343.7 498.1 701.7 1042.4 1934.9
GW: Gestational weeks, Hep(CB): Cord blood hepcidin.signiﬁcantly [14]. Erythropoietin indirectly inﬂuences iron ho-
meostasis. Erythropoietin production as a normal response to
hypoxic stimulation is responsible for normal erythron expansion
without excessive erythropoiesis. Erythropoietin activation is the
main event that occurs in acute hypoxia, which causes the
expansion of erythropoiesis that requires adequate iron for the
hemoglobinization of red cells. The production and hemoglobi-
nization of the erythroid lineage can still occur if hepcidin is
downregulated [15,16].
Among various studies which focused on identifying Hep(CB)
levels based on GW, the results of this study (median 498.1 ng/ml,
10. and 90. percentiles 78.2e1042.4 ng/ml), even though the same
method was used, was remarkably higher compared to that of
Lorenzo et al. [17] (median 103.9 ng/ml, 10. and 90. percentiles
34.4e210.9 ng/ml) and Rehu et al. [18] (median 78.4 ng/ml, 10. and
90. percentiles 29.6e158.9 ng/ml). This study demonstrated that 10
units increase in Hep(CB) levels created a protective effect of 5% in
terms of ID [OR ¼ 0.95 (0.9297e0.98099)]. Cord blood ferritin
T. Gunes et al. / Pediatric Hematology Oncology Journal 1 (2016) 23e2726values, which were analysed simultaneously, were also higher. This
may be associated to the high number of pregnant women who
continued regular monitoring at our hospital.
In a study which compared GW with maternal hepcidin
[Hep(M)] and Hep(CB) levels, it was observed that Hep(M) con-
centration increased as GW increased, and no signiﬁcant differ-
ences was found in Hep(CB) [17,18]. However, in this study, while
Hep(CB) level increased, Hep(M) level decreased as gestational
weeks increased. In a study which included only term newborns
(37e42 gestational weeks), a positive correlation was found be-
tween Hep(M) level and GW (18). The same study reported that no
relationship was observed between Hep(CB) level and GW [18].
However, this study found a negative correlation between Hep(M)
level and GW.
A recent study by Müller et al. analysed Hep(CB) levels of 31
preterm infants younger than 32 gestational weeks and, similar to
our study (n ¼ 60), found out that Hep(CB) levels decreased along
with GW [19]. It is possible to reach lower Hep(CB) levels in preterm
infants, which results from the fact that total iron stores in preterm
infants are lower compared to term infants. Because these infants
stay 8e14 weeks shorter in the womb compared to term infants,
they cannot fully experience last trimester when actual iron
transmission occurs, which accounts for the relationship between
hepcidin level and ironmetabolism in the adults. It is not surprising
that Hep(M) levels were observed to be lower than Hep(CB) levels
in this study.
As this study also demonstrates, Hep(M) is kept at low levels in
order to increase iron absorption and usability to the maximum
level in non-inﬂammatory conditions, which increases iron trans-
mission to the fetus [18]. Rehu et al. reported that hepcidin con-
centration were higher in those who gave birth through vaginal
delivery [18]. No relationship was found between delivery method
and hepcidin in this study. This may have resulted from the fact that
elective caesarean sectionwas used for term gestations, and, on the
other hand, urgent caesarean section was needed for preterm
infants.
A study by McArdle et al. [20] demonstrated that iron trans-
mission continued throughout the gestation. In this study, too, iron
level in the cord blood was measured as normal in each GW even
though maternal iron stores or level were low, indicating that a
hierarchy exists between the mother and fetus. No relationship was
found between cord blood iron level and Hep(M) level in our study.
This may have resulted from the fact that iron stores of infants
included in this study were not under a certain level. On the other
hand, Hep(M) levels were measured as low in 2 infants with very
low ferritin levels (7 ng/ml). Similar to this study, Rehu et al. re-
ported no relationship between Hep(M) levels and infant iron
metabolism.
Previous studies demonstrated that serum hepcidin levels in
patients with sepsis increased and other infection indicators could
be additionally used [21,22]. In a study on pregnant women with
placental malaria infection, Van Santen et al. reported a relation-
ship between Hep(M) and ferritin, iron, iron chelation capacity and
transferrin saturation [23]. Therefore, infection risk was eliminated
through CRP measurement in our group study. In addition, there
was no clinical evidence of infection in pregnant women. Hepcidin
may have the potential advantage to distinguish between anaemia
of inﬂammation and iron-deﬁciency anaemia in practise. Further-
more, it may be useful as an acute phase reactant indicator in cases
with infection and inﬂammation [24].
Ferritin level decreases throughout the gestation, and it reaches
the lowest level in 35the38th week [25]. Ferritin ﬂuctuation may
be caused by physiological factors, independently of iron balance.
Nevertheless, serum ferritin is still the most reliable bio-marker
during gestation [26,27]. A correlation exists between newbornand maternal serum ferritin during the birth. It is envisaged that
newborns with high ferritin levels delivered by mothers receiving
iron treatment are less likely to suffer from ID in their early years
[28]. This study identiﬁed a positive correlation maternal ferritin
level and maternal iron and haemoglobin level. Hepcidin and
ferritin levels increase in parallel with GW, which can be explained
by decreasing iron level. In a study on 120 pregnant women,
Vazirinejad R. et al. compared ferritin level measured 24-h prior to
birth and birth weight. A positive correlation was found between
maternal serum ferritin level and birth weight [29]. On the other
hand, in a study on 63 mothers and 90 preterm infants delivered by
them, Soubasi V. et al. observed a relationship between high
maternal ferritin levels and gestational diabetics and intrauterine
growth restriction [30]. No relationship was found between
maternal ferritin level and birth weight in this study.
Various studies on the development of anaemia of chronic dis-
ease demonstrated that inﬂammatory cytokines and proteins
inﬂuenced iron metabolism. These cytokines display similar effects
during gestation, too [31]. Taking inﬂammatory parameters into
consideration, we included pregnant women without chronic dis-
ease and infection in this study. It is difﬁcult to distinguish between
physiological and ID anaemia during late gestational period [32,33].
Early gestational period is the most suitable period to diagnose
maternal anaemia. Signiﬁcant differences were diagnosed between
women with and without iron deﬁciency in terms of MCV in the
early gestational period; however, no difference was observed in
the third trimester [32]. In this study, too, low iron levels and MCV
values were found in the pregnant women in the third trimester. It
was observed that cord blood MCV levels decreased as GW
increased (p ¼ 0.03), which was considered as a physiological
condition. While MCV value was 180 during the 12th week, it
decreased to 118 during the 34th week. MCV levels decreased as
GW increased [34].
In conclusion, various proteins and elements play role in feto-
placental iron regulation. Therefore, hepcidin hormone, which
plays a key role in iron metabolism, must be analysed. This study
identiﬁed hepcidin hormone level and reference ranges for each
gestational week. It was observed in this study that Hep(CB) level
and GW were related and that hepcidin levels decreased as GW
increased and iron stores decreased. More comprehensive studies
must be carried out in order to beneﬁt from hepcidin hormone
during the treatment in the future.
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